# ADMA Biologics share price today (ADMA Biologics, Inc., ADMA)

> ADMA Biologics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ADMA · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/adma

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $13.21 (−9.0% in a year)
- P/E: 17.1×, over 2.3 years
- Revenue (Jun 2026): $124 M (+2.0% on a year ago)
- Profit (Jun 2026): $37.8 M (+10.5% on a year ago)
- Operating margin: 42.2% (+7.1 points on a year ago)
- ROE: 31%, FY25
- ROIC: 36.5%, against a 7.6% cost of capital: +28.9 points
- Profit that came in as cash: 49%, last 2 years

The main question: profits are rising, but only 49% of the last 2 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the ADMA Biologics share price today? ADMA Biologics, Inc.'s share price was $13.21 at the close on 5 November 2026. It has been stalling near its high for 2 weeks. That is 21.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $8 and $20, and at that close it sat 44% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 14 weeks in a row. Over the last 10 years the share price moved +95% while the S&P 500 moved +245%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does ADMA Biologics pay? ADMA Biologics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is ADMA Biologics on? ADMA Biologics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is ADMA Biologics profitable? ADMA Biologics, Inc. earned $37.8 M of net profit in the Jun 2026 quarter, +10.5% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was $147 M. That is 30.4% of the quarter's revenue. The same quarter a year earlier earned $34.2 M. 1 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $147 M (−25.7% on the year before). Why profit moved: revenue changed +2.0% on a year earlier and the margin moved +7.1 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +6.1% and revenue +8.0%. Profit and revenue are moving at about the same pace. ## How much revenue does ADMA Biologics make, and is it growing? ADMA Biologics, Inc. reported $124 M of revenue in the Jun 2026 quarter, +2.0% on the same quarter a year earlier. Over 4 years it has grown 58.4% a year on average. The last full year, FY25, came in at $510 M. The last four reported quarters add to $512 M. FY25 revenue was $510 M, +19.6% on the year before. Recent pace: the last four quarters grew +8.0% on average, against 58.4% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +8.0%, against +24.5% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −19.1%, against +120.4% a year (rolling over). ## How much of every $100 of sales does ADMA Biologics keep? ADMA Biologics, Inc.'s operating margin was 42.2% in the Jun 2026 quarter, 7.1 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −71.1% and 37.5%. The latest quarter is above every full year in that period. Across 5 years it has been between −71.1% and 37.5%, and FY25's 37.5% is the highest of them. Why the margin moved: operating margin changed +7.1 percentage points on the year while gross margin changed +14.3 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is ADMA Biologics' profit turning into cash? Over the last 2 years, 49% of ADMA Biologics, Inc.'s reported profit came in as cash from its operations, a gap worth watching. In FY25 it brought in $50.4 M of operating cash against $147 M of profit. After $22.6 M of spending on assets, $27.8 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does ADMA Biologics' cash go? ADMA Biologics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $35.6 M on assets over the last 3 years. Averaged over those years that is 2.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $35.6 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is ADMA Biologics' P/E ratio, and how does it compare with its own history? ADMA Biologics, Inc.'s P/E is 17.1×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −25.9% while the price moved −9.0%. The price did better than earnings, which pushed the multiple up within its own range. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the ADMA Biologics business getting better or worse? ADMA Biologics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does ADMA Biologics earn on its capital? ADMA Biologics, Inc. earned a ROE of 31% in FY25. That is up from a low of −51% in FY21. Its return on capital used (ROIC) is 28.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 28.8% net margin and 0.82× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 28.8% net margin × 0.82× asset turnover × 1.31× leverage (assets divided by equity) ≈ 30.9% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 36.5% − 7.6% = +28.9 percentage points. The 7.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 36.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 38.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does ADMA Biologics have too much debt? ADMA Biologics, Inc. has total debt of $204 M against shareholder equity of $408 M as of Jun 2026, so its debt is 0.50× its equity. Year by year, that ratio went from 0.73 in FY21 to 0.17 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the ADMA Biologics shareholding pattern? 8.9% of ADMA Biologics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 5.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is ADMA Biologics from balance-sheet trouble? For ADMA Biologics, Inc., the Z-score is 8.61. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 8.61 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does ADMA Biologics rank in its industry? There is no score against its industry: ADMA Biologics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is ADMA Biologics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to ADMA Biologics in size? ADMA Biologics is the 61st largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Viridian Therapeutics, Inc., Denali Therapeutics Inc. and IDEAYA Biosciences, Inc. Just below it: Zai Lab, AtaiBeckley Inc. and Vericel Corporation. ### Biotechnology companies close in size

1. [Viridian Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/vrdn) $3.2 billion
2. [Denali Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/dnli) $3.2 billion
3. [IDEAYA Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/idya) $3 billion
4. ADMA Biologics, Inc. $2.9 billion
5. [Zai Lab Limited](https://www.sectoralpha.in/us/stocks/zlab) $2.8 billion
6. [AtaiBeckley Inc.](https://www.sectoralpha.in/us/stocks/atai) $2.7 billion
7. [Vericel Corporation](https://www.sectoralpha.in/us/stocks/vcel) $2.7 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Celldex Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/cldx) $2.4 billion · Biotechnology
2. [NETSTREIT Corp.](https://www.sectoralpha.in/us/stocks/ntst) $2.3 billion · REIT - Retail
3. ADMA Biologics, Inc. $2.3 billion
4. [TIC Solutions, Inc.](https://www.sectoralpha.in/us/stocks/tic) $2.3 billion · Specialty Business Services
5. [LiveRamp Holdings, Inc.](https://www.sectoralpha.in/us/stocks/ramp) $2.3 billion · Software - Infrastructure

## What else do people ask about ADMA Biologics? ### What were ADMA Biologics's latest quarterly results? ADMA Biologics, Inc. reported revenue of $124 M and net profit of $37.8 M for the Jun 2026 quarter. Revenue rose 2.0% and profit rose 10.5% compared with a year earlier. Earnings per share were $0.16. The operating margin was 42.2%, 7.1 percentage points higher than a year earlier (as of 5 November 2026). ### What is ADMA Biologics's market cap? ADMA Biologics, Inc.'s market capitalisation is $2.9 B at a stock price of $13.21. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is ADMA Biologics performing? ADMA Biologics, Inc.'s share price has been stalling near its high for 2 weeks. In its latest quarter, revenue rose 2.0% and profit rose 10.5% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 14 weeks running (as of 5 November 2026). ### Will ADMA Biologics's stock price go up? This page does not forecast ADMA Biologics, Inc.'s stock price. What it shows instead: the stock price is $13.21, and it has been stalling near its high for 2 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Does ADMA Biologics have too much debt? ADMA Biologics, Inc. has a moderate amount of debt: its debt is 0.46× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 5 November 2026). ### Where is ADMA Biologics in its business cycle? ADMA Biologics, Inc.'s FY25 operating margin was 37.5%, against a 5-year range of −71.1% to 37.5%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 42.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the ADMA Biologics story? The main question: profits are rising, but only 49% of the last 2 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is ADMA Biologics a stock worth studying right now? What the numbers show: ADMA Biologics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.